Placental Stem Cell Therapy for Neurological Disorders Market Size is valued at USD 384.09 Mn in 2022 and is predicted to reach USD 2,049.44 Mn by the year 2031 at a 20.6% CAGR during the forecast period for 2023-2031.
Placental stem cell therapy for neurological disorders involves using stem cells derived from the placenta to treat various conditions affecting the nervous system. While this field of regenerative medicine shows promise, it is still an area of ongoing research, and clinical applications are not yet widely established. Increased awareness campaigns and educational efforts about the benefits and potential of placental stem cell therapies are raising awareness among healthcare professionals and patients, driving acceptance and adoption. Collaborations between research institutions, healthcare facilities, and biotech companies facilitate translating scientific discoveries into clinical applications, fostering market growth. Patients are increasingly seeking regenerative therapies that offer the potential for improved outcomes and a better quality of life, driving the demand for placental stem cell treatments.
Additionally, stringent regulatory requirements and approval processes can hinder the development and commercialization of placental stem cell therapies for neurological disorders. Meeting these regulatory standards can be time-consuming and costly. The availability of limited clinical data and long-term safety and efficacy data for placental stem cell therapies in treating neurological disorders may raise concerns among healthcare professionals and patients.
The placental stem cell therapy for neurological disorders market is segmented as Type and End-User. Based on type, the market is segmented as allogeneic placental stem cell therapy and autologous placental stem cell therapy. The end users segment consists of hospitals & speciality clinics, clinics, research organizations and research institutes & academics.
The autologous stem cell category will hold a major share in the global placental stem cell therapy for neurological disorders market 2022. Autologous stem cell therapy may provide the potential for long-term benefits, as the patient's cells are more likely to integrate and persist in the body without rejection. Autologous therapies eliminate the risk of disease transmission from donor-derived cells, which can be a concern with allogeneic therapies. This safety advantage is particularly crucial for patients with neurological disorders.
The hospitals & speciality clinics segment is growing rapidly in the global placental stem cell therapy for neurological Disorders market. Hospitals often have specialized medical teams with expertise in neurological disorders. Patients seek out hospitals for placental stem cell therapy due to the availability of skilled neurologists and neurosurgeons who can assess their conditions and recommend appropriate treatments. Hospitals typically have state-of-the-art diagnostic and treatment facilities, including advanced imaging technologies and operating rooms. These resources are essential for accurately diagnosing and effectively administering placental stem cell therapies for neurological disorders.
The North American placental stem cell therapy for neurological disorders market is expected to register the highest market share in revenue soon. Increasing awareness of placental stem cell therapies and their potential benefits has driven patient demand in North America. Patients with neurological disorders are actively seeking alternative treatments, contributing to market growth. Collaborations between academic institutions, healthcare providers, and biotechnology companies have led to establishing specialized centres for placental stem cell therapy in neurological disorders, fostering advancements and accessibility.
In addition, Asia Pacific is estimated to grow rapidly in the global placental stem cell therapy for neurological disorders market. The region benefits from a regulatory framework that facilitates the development and commercialization of regenerative therapies. Regulatory agencies, such as those in this region, have established clear pathways for approving stem cell therapies, providing a conducive environment for market growth.
| Report Attribute | Specifications |
| Market Size Value In 2022 | USD 384.09 Mn |
| Revenue Forecast In 2031 | USD 2,049.44 Mn |
| Growth Rate CAGR | CAGR of 20.6 % from 2023 to 2031 |
| Quantitative Units | Representation of revenue in US$ Mn and CAGR from 2023 to 2031 |
| Historic Year | 2019 to 2022 |
| Forecast Year | 2023-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type, and End-User |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Mesoblast Ltd., Pluristem Therapeutics, ReNeuron Group, AthersysInc., Cordlife India, LifeCell International Pvt. Ltd, Cryo-Cell International Inc., CBR Systems, Cellularity Inc., Cynata |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Placental Stem Cell Therapy for Neurological Disorders Market By Type
Placental Stem Cell Therapy for Neurological Disorders Market By End-User
Placental Stem Cell Therapy for Neurological Disorders Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.